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Prostate cancer-derived urine exosomes: a novel approach to
biomarkers for prostate cancer
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Herein, we describe a novel approach in the search for prostate cancer biomarkers, which relies on the transcriptome within tumour
exosomes. As a proof-of-concept, we show the presence of two known prostate cancer biomarkers, PCA-3 and TMPRSS2:ERG the in
exosomes isolated from urine of patients, showing the potential for diagnosis and monitoring cancer patients status.
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Prostate cancer (PCa) is the only one of the four solid tumour
types, breast, lung and colorectal cancer, which has a clinical useful
protein biomarker for diagnostics and follow-up after treatment.
Prostate-specific antigen (PSA) has shown reasonable sensitivity
for detection of incipient cancer and can also predict response to
treatment (Freedland et al, 2005). One of the drawbacks with PSA
is its low specificity, such that benign hyperplasic conditions can
also be associated with a PSA increase (Catalona et al, 1994). Thus,
additional PCa biomarkers are needed, especially the ones that give
information about the severity of the disease and can predict high
or low risk for future metastases.
In this article, we evaluated a novel approach to find predictive
markers for PCa, and analysed RNA in urine exosomes from PCa
patients. Two types of microvesicles are present in prostate
secretions: (1) prostasomes (150– 500 nm), produced by prostatic
ductal epithelial cells that are a normal component of seminal fluid
and play a role in male fertility (Burden et al, 2006); and (2)
exosomes, specialised nanovesicles (30– 100 nm) with a cup-
shaped morphology, actively secreted by a variety of normal and
tumour cells. Elevated exosome secretion has been found in
malignancy effusions, serum and urine from cancer patients
(Mitchell et al, 2009). In addition, it was shown that exosomes
released from a mast cell line (Valadi et al, 2007) and glioblastoma
tumour cells (Skog et al, 2008) contain intact mRNA that can be
transferred to recipient cells and therein translated into functional
proteins (Skog et al, 2008). Certain RNA transcripts are enriched
several 100-fold in the exosomes compared with the donor cells,
supporting a specific packing mechanism (Skog et al, 2008). The
exosomes lack essentially all of the ribosomal RNA, which
represent B80% of the total RNA in cells, and thus contains
mainly mRNAs and microRNAs (miRNAs). Therefore, exosomes
are enriched in unique transcripts specific to tumour cells that may
be below detection limit even in the tumour cells themselves (Skog
et al, 2008; Taylor and Gercel-Taylor, 2008). In addition, individual
PCa are often very heterogeneous in their phenotype, and a biopsy
taken from one region of the tumour can have a distinct genotype
from another region. Therefore, analysing the transcriptome in
secreted PCa exosomes in urine has the advantages of being both
noninvasive and informative as to the overall tumour malignancy
status, including tumour-specific splice variants, mutations, and
mRNA and miRNA levels known to be diagnostic for PCa.
Other groups have shown that tumour cells shed into the urine
after mild prostate massage can be used as an mRNA source for
the discovery of tumour biomarkers (Hessels et al, 2007; Laxman
et al, 2008). In this study we have taken this concept a step further
to analyse the tumour exosome fraction in urine. Using a nested
PCR-based approach, we were able to show that tumour exosomes
carry genetic information specific for PCa, and as a proof-of-
principle we used tumour exosomes to detect two PCa mRNA
biomarkers, PCA-3 and TMPRSS2:ERG (Hessels et al, 2007;
Laxman et al, 2008). This study supports the use of RNA in
exosomes isolated from urine as diagnostic markers for PCa, and
offers an alternative, sensitive and unique new type of PCa
biomarkers.
MATERIALS AND METHODS
Sample acquisition and microvesicle preparation
Samples were obtained after informed consent. Urine from the
patients was collected before and after receiving prostate massage,
except for patients with bone metastases where only a normal
urine sample was collected. Detailed information about the
patients is presented in Table 1. The microvesicular fraction was
prepared by differential centrifugation. First, cells were pelleted at
500 g for 20 min at 101C and discarded, and then additional cellular
debris was removed by centrifugation at 16 000 g for 20 min at
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101C, followed by filtration through a 0.45mm filter device
(Millipore, Bedford, MA, USA). The microvesicles in the filtrate
were then pelleted by ultracentrifugation (Beckman Coulter AB,
Bromma, Sweden; Ti70 rotor) at 100 000 g for 90 min at 101C. For
electron microscopic studies, the microvesicles were additionally
purified by ultracentrifugation in a 20 and 40% sucrose gradient
and washed with filtered phosphate-buffered saline (PBS).
Electron microscopy
To maximally concentrate the microvesicles, 15 ml drops in PBS
were placed on 2% agarose. Formvar/carbon-coated glow-dis-
charged nickel grids were placed on top of the drops and allowed
to stand for 5–10 min to absorb excess fluid. The grids with
adherent microvesicles were washed and fixed with 2% para-
formaldehyde in PBS for 10 min. For negative staining, the grids
were incubated on ice for 10 min with 25 ml drops of 1.9% methyl
cellulose containing 0.3% uranyl acetate. Excess fluid was removed
before examination with electron microscope. For immunoelectron
microscopy, the microvesicles were incubated for 10 min in
blocking solution (0.1 M glycine and 0.3% bovine serum albumin)
and added to the grids. The microvesicles were incubated
with anti-CD63 monoclonal antibodies (Fitzgerald laboratories,
Concord, MA, USA) or with isotype-matched murine control
antibodies (Dako A/S, DakoCytomation Norden, Glostrup,
Denmark) as a negative control for 1 h. After washing, the grids
were incubated with goat-anti-mouse secondary antibodies con-
jugated with 10 nm-sized gold particles (Sigma-Aldrich Sweden
AB, Stockholm, Sweden) for 1 h. After washing and additional
fixation in 2.5% glutaraldehyde, the grids were negatively stained
as described above.
Total RNA isolation, cDNA synthesis and nested PCR
analysis
Total RNA was extracted from the exosomal or prostasomal pellet
and treated with DNase according to the manufacturer’s recom-
mendations (RNAqueous and TURBO-DNase, Ambion Inc., TX,
USA), and later converted to cDNA (RETROscript, Ambion).
Nested PCR was used to detect transcripts of the selected
biomarkers. In brief, 1.5 ml of the cDNA product was amplified
in a 15 ml reaction, using AmpliTaq DNA polymerase (Applied
Biosystems, Foster City, CA, USA) with the F1/R1 primer set for 40
cycles, then 1.5 ml from the first PCR reaction were amplified with
the F2/R2 primer set for another 40 cycles. Positive samples from
the nested PCR reaction were then re-amplified from the first PCR
reaction for a second time and digested with restriction enzymes to
ensure correct products. The TMPRSS2:ERG PCR products were
re-amplified with the F2/R2 primers, and the product was digested
with Hae-II (New England Biolabs, lpswich, MA, USA) generating
two distinct bands of 54 bp and 68 bp; the PCA-3 PCR products
were re-amplified with the F1/R2 primers and digested with Sca-I
(New England Biolabs), generating two fragments of 90 bp and
62 bp. Each gene product was also cloned into a cloning vector
(pCR4-TOPO, Invitrogen Ltd, Paisley, UK) and sequenced
(BigDye, Applied Biosystems) to further verify the correct gene
product. Primers used are summarised in Table 2.
RESULTS
mRNA analysis of the microvesicular fraction
The patients enroled in this study (Table 1) were divided into four
groups; newly diagnosed without receiving any treatment,
diagnosed and under androgen deprivation therapy (ADT) and
patients with verified bone metastases or patients selected for EM
evaluation. The newly diagnosed cases had not received any kind
of therapeutic treatment, and had detectable PSA mRNA expres-
sion within the urine exosomal fraction (data not shown). In the
newly diagnosed group, two out of the four urine samples were
negative for PSA mRNA transcripts, before mild prostate massage,
whereas all were positive after mild prostate massage (data not
shown), indicating that mild prostate massage increased the
exosomal secretion into the urethra and subsequently into the
collected urine fraction.
The mRNA transcripts for the fusion gene TMPRSS2:ERG were
detected in two out of the four patients who had a high Gleason
Table 1 Diagnostic T-stage, Gleason score, PSA levels (ng ml – 1) before start of treatment
Diagnostic stage
(before any treatment)
PCa biomarkers
(in exosome fraction)
Group Patient Grade Gleason PSA TMPRSS2:ERG PCA-3
Untreated P1 T3,Nx,M0 9 25 + +
P2 T2c,Nx,M0 7 24 + +
P3 T2,Nx,M0 6 7  +
P4 T2,Nx,M0 6 4  +
ADT treated
P5 T3,Nx,M0 7 13  
P6 T2,Nx,M0 7 3  
Verified bone metastases
P7# T2,Nx,M0 7 11  
P8* T3,Nx,M1 8 64  
P9* T2,Nx,M0 8 NA  
EM
P10 T1c,Nx,M0 7 14 NA NA
P11 T3,Nx,M0 8 5 NA NA
ADT¼ androgen deprivation therapy; NA¼ not analysed/not available; PCa¼ prostate cancer; PSA¼ prostate-specific antigen. Patients grouped into four categories; untreated,
treated with androgen deprivation therapy/medical castration (ADT), patients with verified bone metastases, either medically castrated* or prostatectomised#, and patients for
electron microscopy (EM). Detected PCa biomarkers among the patients enroled in pilot study.
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score and PSA levels, and not in the two low-risk tumours (patient
3 and 4), whereas PCA-3 transcripts were detected in all of the
patients after mild prostate massage (Table 1). This is in
accordance with the published finding on PCa biopsies and from
tumour cells in urine (Bussemakers et al, 1999; Nam et al, 2007; Tu
et al, 2007; van Gils et al, 2007). The gene products were analysed
with restriction analysis (Figure 1) together with sequencing of the
products to confirm that the positive bands corresponded to the
appropriate mRNAs (data not shown).
Neither of the ADT patients group (patient 5–6) or the patients
with verified bone metastases (patient 7 –9) had detectable PSA
mRNA levels or were positive for PCA-3 or TMPRSS2:ERG
(Table 1). The loss of biomarker expression in the ADT patient
group correlated with tumour regression and a positive response
to the ADT. The patients with bone metastases had an impaired/
nonfunctional prostate, either after medical castration (patient
8–9) or radical prostatectomy (patient 7). Taken together, these
results show the potential of developing a new method of diagnosis
for PCa by analysis of tumour-specific RNA in tumour exosomes
in urine.
Electron microscopy of the microvesicular fraction
Urine microvesicles from one patient with a low-grade tumour
(patient 10), one patient with a locally high-grade tumour
(patient 11) and one healthy young volunteer were analysed by
electron microscopy. Figures 2A and B illustrate the microvesicular
urine fraction of the healthy donor. Two types of typical
500 nm-sized prostasomes are seen – ‘dark’ prostasomes with
electron-dense contents and inclusions, and ‘light’, less dense ones.
They were CD63 negative after immunogold staining (not shown).
In contrast, microvesicles with cup-shaped morphology and size of
30–100 nm, typical for exosomes, were shown in the microvesi-
cular urine fraction from the high-grade tumour (Figure 2C). Their
exosomal nature was confirmed by immunoelectron microscopy
after anti-CD63 gold staining (Figure 2D). The visual impression
was that the exosome amount was enriched after prostate massage
(not shown). It is interesting that, prostasomes were not found in
the urine of PCa patients and vice versa; exosomes were not
present in the urine of healthy donors. No exosomes or
prostasomes were found in the PCa patient with the low-grade
tumour (not shown). From these experiments we conclude
that PCa-derived exosomes are present in the urine of PCa
patients and that these can be used for analysis of the tumour
transcriptome.
DISCUSSION
To validate the concept of urine exosomes as carriers of genetic
information and a potential source of new cancer biomarkers,
especially for PCa, we carried out a pilot study to investigate
whether we could amplify two prognostic mRNA biomarkers. One
of these has been shown to be overexpressed in PCa-PCA-3
(de Kok et al, 2002) and the other is a product of a chromosomal
rearrangement, which creates a common prostate cancer-specific
product, the TMPRSS2:ERG fusion (Tomlins et al, 2005). By
reverse transcription –PCR analysis of RNA in the exosome
fraction from PCa patients, we were able to monitor the status of
these two established biomarkers from a very limited amount of
exosomal RNA. This study establishes the potential to use the RNA
content of tumour exosomes derived from urine to provide a
window into the tumour status, both with respect to tumour
genotype/phenotype and metastatic potential. This delineation of
the tumour genotype/phenotype can provide information to the
clinician both with respect to diagnosis and treatment paradigms
(Skog et al, 2008). Potentially the response to ADT could also be
followed, assuming that regression of the tumour resulted in less/
no expression of the biomarkers, but the loss of expression could
also be because of the reduced expression of androgen-responsive
genes, like TMPRSS2 and PCA3 (Tomlins et al, 2005; Shaw et al,
2007). That is an important distinction and further studies are
needed to address this question.
Tumour exosomes are distinct from exosomes shed by normal
cells, in particular, they are more abundant in cancer patients, and
the exosomes shed from tumours seems to have an important role
in the increased tumour growth, angiogenesis and the escape from
the immune-surveillance (Abusamra et al, 2005; Liu et al, 2006;
TMPRSS2:ERG
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Figure 1 Restriction enzyme analysis of the positive PCR products. (A)
Positive tumour samples (P1 and P2) for the TMPRSS2:ERG gene fusion
showing fragment sizes after digestion with HaeII, 68 bp and 54 bp (right
lane) and the undigested product, 122 bp (left lane). (B) Positive samples
for the PCA-3 gene product before and after digestion with Sca1, fragment
sizes after digestion with Sca1 were 90 bp and 62 bp (left lane), and the
uncut fragment size was 152 bp (right lane).
Table 2 Sequences of primers used for the different PCR applications and their Genbank accession number
Gene name
Gene name
abbreviation
Genbank accession
number Sequence Primer source
TMPRSS2/ERGa fusion transcript TMPRSS2:ERG DQ204772 F1 50-TAGGCGCGAGCTAAGCAGGAG-30 (Tomlins et al, 2005; Tu et al, 2007)
F2 50-CGCGAGCTAAGCAGGAGGC-30 (Tu et al, 2007)
R1 50-GGGGGTTGAGACAGCCAATC-30 (Rozen and Skaletsky, 2000)
R2 50-GTAGGCACACTCAAACAACGACTGG-30 (Tomlins et al, 2005; Tu et al, 2007)
Prostate cancer antigen 3 PCA-3 AF103907 F1 50- AGTCCGCTGTGAGTCT-30 (Rozen and Skaletsky, 2000)
F2 50-ATCGACGGCACTTTCTGAGT-30
R1 50-CCATTTCAGCAGATGTGTGG-30
R2 50-TGTGTGGCCTCAGATGGTAA-30
The primers were generated using PRIMER-3 (Rozen and Skaletsky, 2000), or found in the literature as described under primer source. F2 and R2 refer to the nested primers.
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Skog et al, 2008). RNA extracted from the tumour exosomes
contains a ‘snap-shot’ of the tumour transcriptome (Skog et al,
2008). Using exosomes from urine we can then, potentially, extend
the available biomarkers to include mRNAs and miRNAs, not only
for cancer detection, but also to try to classify the severity of the
tumour phenotype and follow the tumour response to treatment.
The results presented within this pilot study warrant further
research to determine the use of urine exosomes in diagnostics and
tumour surveillance of PCa.
ACKNOWLEDGEMENTS
This work was supported by grants from Swedish Cancer Research
Foundation (Project Nr. 070604 AW and Nr. 080560 LM-N),
Wenner-Gren Foundation (JS), Stiftelsen Olle Engkvist Byggma¨stare
(JS), NCI CA86355 (XOB), NCI CA69246 (XOB) and the Lions
Research Foundation, Umea˚ University, Sweden (AW, JN, LM-N).
The patients participating in the study are gratefully acknowledged.
JS is also a consultant for Exosome Diagnostics Inc.
REFERENCES
Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP (2005)
Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis.
Blood Cells Mol Dis 35: 169 – 173
Burden HP, Holmes CH, Persad R, Whittington K (2006) Prostasomes—
their effects on human male reproduction and fertility. Hum Reprod
Update 12: 283 – 292
Bussemakers MJG, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus
HFM, Schalken JA, Debruyne FMJ, Ru N, Isaacs WB (1999) DD3:a new
prostate-specific gene, highly overexpressed in prostate cancer. Cancer
Res 59: 5975 – 5979
Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan
RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB,
MacFarlane MT, Southwick PC (1994) Selection of optimal prostate
specific antigen cutoffs for early detection of prostate cancer: receiver
operating characteristic curves. J Urol 152: 2037 – 2042
de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders
TW, Swinkels DW, Schalken JA (2002) DD3PCA3, a very sensitive and
specific marker to detect prostate tumors. Cancer Res 62: 2695 – 2698
Freedland SJ, Mangold LA, Walsh PC, Partin AW (2005) The prostatic
specific antigen era is alive and well: prostatic specific antigen and
biochemical progression following radical prostatectomy. J Urol 174:
1276 – 1281
Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA
(2007) Detection of TMPRSS2-ERG fusion transcripts and prostate
cancer antigen 3 in urinary sediments may improve diagnosis of prostate
cancer. Clin Cancer Res 13: 5103 – 5108
Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ,
Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM (2008) A first-
generation multiplex biomarker analysis of urine for the early detection
of prostate cancer. Cancer Res 68: 645 – 649
Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly
RP, Grizzle WE, Zhang HG (2006) Murine mammary carcinoma
exosomes promote tumor growth by suppression of NK cell function.
J Immunol 176: 1375 – 1385
Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A
(2009) Can urinary exosomes act as treatment response markers in
prostate cancer? J Transl Med 7: 4
Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic
A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A
(2007) Expression of the TMPRSS2:ERG fusion gene predicts cancer
recurrence after surgery for localised prostate cancer. Br J Cancer 97:
1690 – 1695
Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and
for biologist programmers. Methods Mol Biol 132: 365 – 386
A
C D
B
Figure 2 Electron microscopy of microvesicles isolated from urine of healthy donor (A and B) and PCa patient (patient nr. 11, C and D). (A)
Microvesicles from healthy donor displaying the typical size (150–500 nm) and ultrastructure of electron-dense and electron-lucent prostasomes (arrows).
(B) At high magnification, note the limiting membrane (arrowheads) and the unstructured matrix (star) of prostasomes. (C) Urine microvesicles from PCa
patient showing small size (30–100 nm) and cup-shaped morphology (arrowheads) characteristic of exosomes. (D) Immunoelectron micrograph showing
the presence of the typical surface exosomal marker CD63 on the microvesicles (arrowheads). Bars: A, B 500 nm; C, D 100 nm.
A novel approach in the search for prostate cancer biomarkers
J Nilsson et al
1606
British Journal of Cancer (2009) 100(10), 1603 – 1607 & 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
Shaw G, Oliver RTD, Purkiss T, Prowse DM (2007) Re: Christine
McKillop. Interview with Jack Schalken: PCA3 and its use as a
diagnostic test in prostate cancer. Eur Urol 51: 860 – 862
Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M,
Curry Jr WT., Carter BS, Krichevsky AM, Breakefield XO (2008)
Glioblastoma microvesicles transport RNA and proteins that promote
tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:
1470 – 1476
Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:
13 – 21
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW,
Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB,
Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of
TMPRSS2 and ETS transcription factor genes in prostate cancer. Science
310: 644 – 648
Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT (2007) Gene
fusions between TMPRSS2 and ETS family genes in prostate cancer:
frequency and transcript variant analysis by RT-PCR and FISH on
paraffin-embedded tissues. Mod Pathol 20: 921 – 928
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007)
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol 9: 654 – 659
van Gils MPMQ, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ,
Witjes JA, Cornel EB, Karthaus HFM, Smits GAHJ, Dijkman GA, Mulders
PFA, Schalken JA (2007) The time-resolved fluorescence-based PCA3 test on
urinary sediments after digital rectal examination; a Dutch multicenter
validation of the diagnostic performance. Clin Cancer Res 13: 939 – 943
A novel approach in the search for prostate cancer biomarkers
J Nilsson et al
1607
British Journal of Cancer (2009) 100(10), 1603 – 1607& 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
